Online citations, reference lists, and bibliographies.
← Back to Search

Immunization Of Mice With Lipopeptide Antigens Encapsulated In Novel Liposomes Prepared From The Polar Lipids Of Various Archaeobacteria Elicits Rapid And Prolonged Specific Protective Immunity Against Infection With The Facultative Intracellular Pathogen, Listeria Monocytogenes.

J. Conlan, L. Krishnan, G. Willick, G. B. Patel, G. Sprott
Published 2001 · Biology, Medicine

Cite This
Download PDF
Analyze on Scholarcy
Share
Protective immunity to intracellular bacterial pathogens usually requires the participation of specific CD8+ T cells. Natural exposure of the host to sublethal infection, or vaccination with attenuated live vaccines are the most effective means of eliciting prolonged protective cell-mediated immunity against this class of pathogens. The ability to replace these immunization strategies with defined sub-unit vaccines would represent a major advance for clinical vaccinology. The present study examines the ability of novel liposomes, termed archaeosomes, made from the polar lipids of various Archaeobacteria to act as self-adjuvanting vaccine delivery vehicles for such defined acellular antigens. Using infection of mice with Listeria monocytogenes as a model system, this study clearly demonstrates the ability of defined, archaeosome-entrapped antigens to elicit rapid and prolonged specific immunity against a prototypical intracellular pathogen. In this regard, all of the tested archaeosomes were superior to conventional liposomes.
This paper references
Controlled lipidation and encapsulation of peptides as a useful approach to mucosal immunizations.
A. Mora (1998)
10.1016/0022-1759(95)00052-C
Monopalmitic acid-peptide conjugates induce cytotoxic T cell responses against malarial epitopes: importance of spacer amino acids.
A. Verheul (1995)
T cell responses to Gram-negative intracellular bacterial pathogens: a role for CD8+ T cells in immunity to Salmonella infection and the involvement of MHC class Ib molecules.
W. F. Lo (1999)
10.1128/IAI.60.1.95-101.1992
Free versus liposome-encapsulated muramyl tripeptide phosphatidylethanolamide in treatment of experimental Klebsiella pneumoniae infection.
P. Melissen (1992)
10.1128/IAI.60.3.951-957.1992
Roles of Listeria monocytogenes virulence factors in survival: virulence factors distinct from listeriolysin are needed for the organism to survive an early neutrophil-mediated host defense mechanism.
J. Conlan (1992)
10.1038/NBT1184-979
Dehydration-Rehydration Vesicles: A Simple Method for High Yield Drug Entrapment in Liposomes
C. Kirby (1984)
10.1128/IAI.64.5.1685-1693.1996
A recombinant minigene vaccine containing a nonameric cytotoxic-T-lymphocyte epitope confers limited protection against Listeria monocytogenes infection.
L. L. An (1996)
10.1128/IAI.60.12.5164-5171.1992
Early pathogenesis of infection in the liver with the facultative intracellular bacteria Listeria monocytogenes, Francisella tularensis, and Salmonella typhimurium involves lysis of infected hepatocytes by leukocytes.
J. Conlan (1992)
10.1084/JEM.132.3.535
SUPPRESSION OF CELL-MEDIATED IMMUNITY TO INFECTION BY AN ANTIMITOTIC DRUG
R. North (1970)
10.1007/BF00762348
Structures of archaebacterial membrane lipids
G. Sprott (1992)
10.1016/S0264-410X(98)00250-3
Lipopeptide particles as the immunologically active component of CTL inducing vaccines.
Ikuo Tsunoda (1999)
10.4049/jimmunol.165.9.5177
Archaeosomes Induce Long-Term CD8+ Cytotoxic T Cell Response to Entrapped Soluble Protein by the Exogenous Cytosolic Pathway, in the Absence of CD4+ T Cell Help1
L. Krishnan (2000)
10.1073/PNAS.93.22.12531
Anthrax toxin-mediated delivery of a cytotoxic T-cell epitope in vivo.
J. Ballard (1996)
10.1080/0738-859991229170
Archaeobacterial ether lipid liposomes (archaeosomes) as novel vaccine and drug delivery systems.
Patel Gb (1999)
10.1016/0022-1759(89)90198-1
Specific assays for cytokine production by T cells.
T. Mosmann (1989)
Cutting edge: paradigm revisited: antibody provides resistance to Listeria infection.
B. Edelson (1999)
Experimental Listeria enteritis. I. An electron microscopic study of the epithelial phase in experimental listeria infection.
P. Rácz (1972)
10.1021/JM960743O
Bioactivities and secondary structures of constrained analogues of human parathyroid hormone: cyclic lactams of the receptor binding region.
J. Barbier (1997)
Genetic immunization of mice against Listeria monocytogenes using plasmid DNA encoding listeriolysin O.
Kenneth A. Cornell (1999)
10.1038/15058
Advances in vaccine adjuvants
M. Singh (1999)
10.1084/JEM.116.3.381
CELLULAR RESISTANCE TO INFECTION
G. Mackaness (1962)
10.1128/IAI.68.1.54-63.2000
Archaeosome Vaccine Adjuvants Induce Strong Humoral, Cell-Mediated, and Memory Responses: Comparison to Conventional Liposomes and Alum
L. Krishnan (2000)
10.1038/353852A0
Precise prediction of a dominant class I MHC-restricted epitope of Listeria monocytogenes
E. Pamer (1991)
10.1126/SCIENCE.285.5428.732
Host defense mechanisms triggered by microbial lipoproteins through toll-like receptors.
H. Brightbill (1999)
10.1073/PNAS.93.4.1458
Superior efficacy of secreted over somatic antigen display in recombinant Salmonella vaccine induced protection against listeriosis.
J. Heß (1996)
10.1128/IAI.62.12.5603-5607.1994
CD4+ and CD8+ T-cell-dependent and -independent host defense mechanisms can operate to control and resolve primary and secondary Francisella tularensis LVS infection in mice.
J. Conlan (1994)
10.1111/j.1600-065X.1997.tb00989.x
Murine listeriosis as a model of antimicrobial defense
R. North (1997)
Role of innate and adaptive immunity in the outcome of primary infection with Chlamydia pneumoniae, as analyzed in genetically modified mice.
M. Rottenberg (1999)
10.1016/S0171-2985(99)80057-6
Early host-pathogen interactions in the liver and spleen during systemic murine listeriosis: an overview.
J. Conlan (1999)
10.1126/SCIENCE.276.5319.1684
Differential effects of cytolytic T cell subsets on intracellular infection.
S. Stenger (1997)
Control of IL-12 and IFN-gamma production in response to live or dead bacteria by TNF and other factors.
Y. Zhan (1998)
10.1016/0165-2478(94)90179-1
The immunodominant peptide from listeriolysin in Quil A liposomes vaccinates CD8+ cytolytic T cells and confers protection to infection.
G. Lipford (1994)
10.1159/000058697
Immunity to Listeria monocytogenes
R. North (1998)
10.4049/jimmunol.164.2.900
Extension of HLA-A*0201-Restricted Minimal Epitope by Nε-Palmitoyl-lysine Increases the Life Span of Functional Presentation to Cytotoxic T Cells1
E. Loing (2000)



This paper is referenced by
10.2174/187221409789104728
Recent Patents on Oral Vaccine Design
S. Mangal (2009)
10.1081/LPR-120016712
SAFETY OF ARCHAEOSOME ADJUVANTS EVALUATED IN A MOUSE MODEL*
G. B. Patel (2002)
Induction of Strong and Specific Humoral and T-helper 1 Cellular Responses by HBsAg Entrapped in the Methanobrevibacter smithii Archaeosomes
M. R. Aghasadeghi (2014)
10.1155/2003/569283
Archaeosomes varying in lipid composition differ in receptor-mediated endocytosis and differentially adjuvant immune responses to entrapped antigen.
G. Sprott (2003)
10.1155/2010/242539
Recent Advancements in Cytotoxic T Lymphocyte Generation Methods Using Carbohydrate-Coated Liposomes
Y. Ikehara (2010)
10.1080/14760584.2016.1195265
Archaeal lipid vaccine adjuvants for induction of cell-mediated immunity
K. Haq (2016)
10.3389/fimmu.2018.00431
Lipid-Based Particles: Versatile Delivery Systems for Mucosal Vaccination against Infection
B. Corthésy (2018)
10.1038/NPG.ELS.0004316
Archaeal Membrane Lipids
G. B. Patel (2006)
10.1016/j.vaccine.2019.07.010
Archaeal glycolipid adjuvanted vaccines induce strong influenza-specific immune responses through direct immunization in young and aged mice or through passive maternal immunization.
Felicity C Stark (2019)
10.3390/vaccines7040204
Effect of Different Adjuvants on the Longevity and Strength of Humoral and Cellular Immune Responses to the HCV Envelope Glycoproteins
Bassel Akache (2019)
10.1201/9780849397271-10
Coupling of Peptides to the Surface of Liposomes— Application to Liposome-Based Synthetic Vaccines
Francis J. Schuber (2016)
10.5772/INTECHOPEN.69390
Liposome-Mediated Immunosuppression Plays an Instrumental Role in the Development of “Humanized Mouse” to Study Plasmodium falciparum
Kunjal Agrawal (2017)
10.1128/9781555815813.CH8
Membrane Adaptations of (Hyper)Thermophiles to High Temperatures
A. Driessen (2007)
10.9734/ARRB/2014/7611
Application Potential of Liposomal Delivery Systems Prepared by Lipids Extracted from E.coli Cultures
M. Kargar (2014)
10.1016/J.VACCINE.2003.11.054
Liposome adjuvants prepared from the total polar lipids of Haloferax volcanii, Planococcus spp. and Bacillus firmus differ in ability to elicit and sustain immune responses.
G. Sprott (2004)
10.1023/A:1016104910582
Recent Advances in Vaccine Adjuvants
M. Singh (2004)
10.1002/PMIC.200401123
Proteomic analysis of anti‐Francisella tularensis LVS antibody response in murine model of tularemia
J. Havlasová (2005)
10.1201/B18654-5
Liposomes as a Drug Delivery System
Kacoli Banerjee (2015)
10.4161/hv.22780
Archaeosomes display immunoadjuvant potential for a vaccine against Chagas disease
L. Higa (2013)
10.4049/jimmunol.173.1.566
Phosphatidylserine Receptor-Mediated Recognition of Archaeosome Adjuvant Promotes Endocytosis and MHC Class I Cross-Presentation of the Entrapped Antigen by Phagosome-to-Cytosol Transport and Classical Processing1
K. Gurnani (2004)
10.3390/biomedicines7040091
Simplified Admix Archaeal Glycolipid Adjuvanted Vaccine and Checkpoint Inhibitor Therapy Combination Enhances Protection from Murine Melanoma
Felicity C Stark (2019)
10.1007/978-1-4020-5041-1_2
Archaeosomes as Drug and Vaccine Nanodelivery Systems
G. B. Patel (2006)
10.18433/J3CP55
Liposomal drug delivery: a versatile platform for challenging clinical applications.
Asadullah Madni (2014)
10.1080/21645515.2017.1316912
Sulfated archaeal glycolipid archaeosomes as a safe and effective vaccine adjuvant for induction of cell-mediated immunity
M. McCluskie (2017)
10.1016/j.bbrc.2010.03.041
Investigation of archaeosomes as carriers for oral delivery of peptides.
Z. Li (2010)
10.1016/j.arcmed.2015.06.004
Reality of a Vaccine in the Prevention and Treatment of Atherosclerosis.
V. García-González (2015)
10.1016/J.VACCINE.2007.09.042
Mucosal and systemic immune responses by intranasal immunization using archaeal lipid-adjuvanted vaccines.
G. B. Patel (2007)
10.1371/journal.pone.0208067
Sulfated archaeol glycolipids: Comparison with other immunological adjuvants in mice
Bassel Akache (2018)
10.1002/9781118114063.CH12
Peptide Nanotubes in Biomedical and Environmental Applications
Byung-wook Park (2011)
10.1080/21645515.2020.1788300
Mechanistic insight into the induction of cellular immune responses by encapsulated and admixed archaeosome-based vaccine formulations
Gerard Agbayani (2020)
10.1016/S0264-410X(02)00540-6
Liposomes and ISCOMs.
G. Kersten (2003)
10.1586/erv.10.34
Archaeal lipid mucosal vaccine adjuvant and delivery system
G. B. Patel (2010)
See more
Semantic Scholar Logo Some data provided by SemanticScholar